Moderna Advances COVID-19 Vaccine Development

Headline Roundup October 29th, 2020

Moderna executives said in a press release Thursday that the company is on track to report early data from a late-stage trial of its experimental COVID-19 coronavirus vaccine, after initial results of its 30,000 person trial come in. The company said it expects to apply for authorization from the Food and Drug Administration (FDA) in early December if all requirements are met. The FDA requires a 50 percent efficacy rate for approval, though Moderna said it wants to have at least a 75 percent efficacy rate overall. The company expects the vaccine to be widely available in 2021; Moderna stock went up by 3 percent after its announcement Thursday, and the company is already taking in $1.1 billion in deposits from countries around the globe.

The story was widely covered by outlets on all sides of the political spectrum; some left-rated outlets focused on the news in the context of the Trump administration's Operation Warp Speed project.

Moderna Advances COVID-19 Vaccine Development

From the Right
13320

Moderna Inc, one of the front-runners in the race to develop a vaccine for the new coronavirus, said on Thursday it was preparing to launch the experimental vaccine and had already received $1.1 billion in deposits for supply.

The Cambridge, Massachusetts-based company has signed deals with the U.S. government and several other countries, and is in talks with a WHO-led group for supply of the vaccine, which is in large, late-stage human trials.

While the company did not give a clear timeline on the release of data from these trials...

Read full story
From the Center
13320

Moderna is on track to report initial results from its coronavirus vaccine trial next month, company executives said Thursday.

The company is one of the front-runners to produce a vaccine for COVID-19. During an earnings call, Chief Medical Officer Tal Zaks said the trial is operating as planned, and an independent data-monitoring committee is expected to conduct an interim review in November.

The first review from the board will come after the trial reports that 53 cases of COVID-19 have been diagnosed among its sample, and the second interim analysis...

Read full story
From the Left
13320
ANALYSIS

On a late August day in an industrial corner of Baltimore that had been mostly silenced by the pandemic, a red-brick manufacturing plant was buzzing with activity. Deep in the building, in a zone called Area 3, the stainless steel shell of a bioreactor lay on its side, having just arrived from Massachusetts. Employees had begun the task of making the bioreactor operational. Within weeks it would be the center of a production line for coronavirus vaccines.

Read full story

Try the New AllSides Mobile App

The only news app you’ll ever need. Now available on iOS. Android version coming soon.